ArticleFrontiers in immunology2026
Hepatitis B virus infection and outcomes of TACE plus lenvatinib and PD-1 inhibitor therapy in unresectable hepatocellular carcinoma: a real-world propensity score-matched study.
Article in Frontiers in immunology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: The combination of transarterial chemoembolization (TACE), lenvatinib, and PD-1 inhibitors has shown promising efficacy in treating advanced hepatocellular carcinoma (HCC). However, the impact of hepatitis B virus (HBV) infection on the outcomes of this therapy remains unclear. This study aims to assess the association between HBV infection status and clinical outcomes in patients with initially unresectable HCC undergoing triple therapy. Methods: This retrospective single-center cohort study included 190 consecutive uHCC patients treated with triple therapy between February 2022 and February 2025. Patients were stratified into HBV-positive (n = 133) and HBV-negative (n = 57) groups based on HBsAg status. Propensity score matching (PSM, 1:1, caliper 0.02) was performed to balance baseline characteristics. The primary endpoint was surgical conversion. Secondary endpoints included tumor response (mRECIST), overall survival (OS), progression-free survival (PFS), and treatment-related adverse events (AEs). Landmark analyses, subgroup analyses and multivariate Cox regression were used to evaluate clinical outcomes and independent prognostic factors. Results: Compared to HBV-negative patients, HBV-positive patients achieved significantly higher surgical conversion rates both before PSM (25.6% vs. 12.3%, P = 0.041) and after PSM (20% vs. 10%, P = 0.021). After PSM, 30 matched pairs were included. Median OS was not reached in the HBV-positive patients and was 20.0 months in the HBV-negative patients (95% CI, 17.1-22.9; P = 0.014). Median PFS was 28.4 months (95% CI, 25.6-31.2) versus 17.3 months (95% CI, 14.8-19.9; P = 0.030). Tumor response was superior in the HBV-positive group, with higher ORR (36.7% vs. 20%, P = 0.043) and DCR (83.3% vs. 60%, P = 0.045). HBV-positive patients exhibited significantly prolonged OS (P = 0.014) and PFS (P = 0.030). Landmark analysis showed that the PFS advantage in HBV-positive patients no longer statistically significant (P = 0.118). Tumor diameter and HBV infection status were independent predictor of OS and PFS. Grade 3-4 AEs were comparable between groups, and no treatment-related deaths occurred. Conclusions: HBV-positive status was associated with higher conversion rates and more favorable survival outcomes in unresectable HCC treated with TACE, lenvatinib, and PD-1 inhibitors. Prospective validation is needed to confirm these findings and clarify their biological basis.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.